Sanders Profiled in DCA Live About Navigating the Life and Work During the COVID-19 Pandemic
25 March 2020
Partner David Sanders discussed with DCA Live founder and CEO Doug Anderson how he is navigating working remotely and family life during the COVID-19 Pandemic.
Sanders said he sees several new opportunities and ventures that might be created out of the health crisis including a greater acceptance of telehealth platforms, a permanent bump for life sciences companies and a permanent increase in the use of online learning platforms and video communication platforms.
Sanders told Anderson that several things are helping him maintain morale and productivity through this crisis, including “Weekly group calls; Foley’s Daily News featuring tips on remote working and occasional comic relief regarding the current situation; calls with team members at least every other day to maintain personal contact and physical activity.”
And the one thing he is looking forward to once it’s safe to resume normal life? Playing ice hockey
DCA Live hosts events that engage the people and companies that are driving growth in the Washington, D.C. economy and counts over 12,000 business professionals as members since it was created in 2014.
The entire profile was shared on Anderson’s LinkedIn.
People
Related News
08 May 2024
In the News
Benjamin Dryden on Noncompete Ban – Expect Trade Secret Litigation Increase in ‘Volume and Nastiness’
Foley & Lardner LLP partner Benjamin Dryden offered insight on the specific impact to the manufacturing sector of the U.S. Federal Trade Commission’s (FTC) recently issued final rule banning noncompete agreements
08 May 2024
In the News
Foley Real Estate, Hospitality Transactions Highlighted in Golf Inc.
Foley & Lardner LLP served as legal advisor on two of Golf Inc.’s Top 10 Sales of 2023.
08 May 2024
In the News
Kyle Faget Assesses FDA Rule Regulating Lab-Developed Tests, Potential Challenges
Foley & Lardner LLP partner Kyle Faget offers insight on potential challenges to the U.S. Food and Drug Administration’s (FDA) final rule regulating lab-developed tests (LDTs)